{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:04:42Z","timestamp":1779955482367,"version":"3.53.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009888","name":"Regione Toscana","doi-asserted-by":"publisher","award":["K38"],"award-info":[{"award-number":["K38"]}],"id":[{"id":"10.13039\/501100009888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jcf.2025.06.002","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T23:41:48Z","timestamp":1750894908000},"page":"861-866","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Monitoring early antibiotic treatment with anti-Pseudomonas aeruginosa serology: a comparison of two specific antibody panels"],"prefix":"10.1016","volume":"24","author":[{"given":"Daniela","family":"Dolce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3642-8928","authenticated-orcid":false,"given":"Cristina","family":"Fevola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Francalanci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bonomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Galici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Silvia","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1106-4424","authenticated-orcid":false,"given":"Vito","family":"Terlizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Taccetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.jcf.2025.06.002_bib0001","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic Fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N Engl J Med"},{"issue":"10290","key":"10.1016\/j.jcf.2025.06.002_bib0002","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jcf.2025.06.002_bib0003","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","article-title":"Cystic fibrosis","volume":"10","author":"Mall","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jcf.2025.06.002_bib0004","unstructured":"ECFSPR Annual Report 2022, Zolin A., Adamoli A., Bakkeheim E., van Rens J. et al. https:\/\/www.ecfs.eu\/sites\/default\/files\/Annual%20Report_2022_ECFSPR_20240603.pdf Accessed 20 February 2025."},{"issue":"2","key":"10.1016\/j.jcf.2025.06.002_bib0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.06.002_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.01.005","article-title":"Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues","author":"Burgel","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.06.002_bib0007","unstructured":"Laboratory Standards for Processing Microbiological Samples from People with Cystic Fibrosis. Second edition December 2022 https:\/\/www.cysticfibrosis.org.uk\/sites\/default\/files\/2023-01\/CF%20Lab%20Standards%20FINAL.pdf Accessed 20 February 2025."},{"issue":"3","key":"10.1016\/j.jcf.2025.06.002_bib0008","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00215-21","article-title":"Practical guidance for clinical microbiology laboratories: updated guidance for processing respiratory tract samples from people with cystic fibrosis","volume":"12","author":"Saiman","year":"2024","journal-title":"Clin Microbiol Rev"},{"issue":"7","key":"10.1016\/j.jcf.2025.06.002_bib0009","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/ppul.23715","article-title":"Risk factors for mortality before age 18 years in cystic fibrosis","volume":"52","author":"McColley","year":"2017","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.jcf.2025.06.002_bib0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jcf.2021.09.017","article-title":"Risk factors for Pseudomonas aeruginosa airway infection and lung function decline in children with cystic fibrosis","volume":"21","author":"M\u00e9sin\u00e8le","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcf.2025.06.002_bib0011","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ijmm.2010.08.010","article-title":"Prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"300","author":"D\u00f6ring","year":"2010","journal-title":"Int J Med Microbiol"},{"issue":"1","key":"10.1016\/j.jcf.2025.06.002_bib0012","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","article-title":"Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"2","author":"Lee","year":"2003","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2025.06.002_bib0013","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","volume":"6","author":"Langton Hewer","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jcf.2025.06.002_bib0014","unstructured":"The UK Cystic Fibrosis Trust Infection Control Group. Pseudomonas aeruginosa infection in people with cystic fibrosis. suggestions for prevention and infection control. second edition. Bromley UK. Cystic Fibrosis Trust; 2004. https:\/\/www.cysticfibrosis.org.uk\/sites\/default\/files\/2020-12\/Pseudomonas%20aeruginosa.pdf Accessed 20 February 2025."},{"issue":"5","key":"10.1016\/j.jcf.2025.06.002_bib0015","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/cid\/civ377","article-title":"Impact of sustained eradication of new Pseudomonas aeruginosa infection on long-term outcomes in cystic fibrosis","volume":"61","author":"Mayer-Hamblett","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jcf.2025.06.002_bib0016","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jcf.2014.08.001","article-title":"Early detection of infection with Pseudomonas aeruginosa in cystic fibrosis: the Holy Grail or an achievable goal?","volume":"13","author":"Taccetti","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2025.06.002_bib0017","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jcf.2014.01.005","article-title":"Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis as a diagnostic tool: a systematic review","volume":"13","author":"Mauch","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.06.002_bib0018","unstructured":"Anti - Pseudomonas aeruginosa IgG ELISA https:\/\/mediagnost.de\/wp-content\/uploads\/2023\/08\/IFU-E15-IVD-D_E-5.pdf Accessed 20 February 2025."},{"issue":"3","key":"10.1016\/j.jcf.2025.06.002_bib0019","first-page":"298","article-title":"Identification and quantitation of precipitins against Pseudomonas aeruginosa in patients with cystic fibrosis by means of crossed immunoelectrophoresis with intermediate gel","volume":"81","author":"Hoiby","year":"1973","journal-title":"Acta Pathol Microbiol Scand B Microbiol Immunol"},{"issue":"3","key":"10.1016\/j.jcf.2025.06.002_bib0020","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jcf.2023.11.012","article-title":"Downey DG inhaled antimicrobial prescribing for Pseudomonas aeruginosa infections in Europe","volume":"23","author":"Sloan","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.06.002_bib0021","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 12.0, 2022 http:\/\/www.eucast.org\/clinical_breakpoints\/n.d. Accessed 20 February 2025."},{"issue":"1","key":"10.1016\/j.jcf.2025.06.002_bib0022","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1128\/iai.42.1.197-201.1983","article-title":"Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis","volume":"42","author":"D\u00f6ring","year":"1983","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.jcf.2025.06.002_bib0023","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/ppul.20562","article-title":"Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"42","author":"Ratjen","year":"2007","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"10.1016\/j.jcf.2025.06.002_bib0024","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/thx.2005.054726","article-title":"Diagnostic value of serological tests against Pseudomonas aeruginosa in a large cystic fibrosis population","volume":"61","author":"Tramper-Stranders","year":"2006","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.jcf.2025.06.002_bib0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jcf.2008.08.002","article-title":"Diagnostic significance of measurements of specific IgG antibodies to Pseudomonas aeruginosa by three different serological methods","volume":"8","author":"Pressler","year":"2009","journal-title":"J Cyst Fibros"},{"issue":"11","key":"10.1016\/j.jcf.2025.06.002_bib0026","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1136\/thx.2009.132845","article-title":"Value of serology in predicting Pseudomonas aeruginosa infection in young children with cystic fibrosis","volume":"65","author":"Douglas","year":"2010","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.jcf.2025.06.002_bib0027","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jcf.2012.08.001","article-title":"Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial","volume":"12","author":"Anstead","year":"2013","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2025.06.002_bib0028","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jcf.2014.06.005","article-title":"Serology as a diagnostic tool for predicting initial Pseudomonas aeruginosa acquisition in children with cystic fibrosis","volume":"13","author":"Daines","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2025.06.002_bib0029","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jcf.2014.06.006","article-title":"Predictive values of antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis one year after early eradication treatment","volume":"13","author":"Kappler","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"22","key":"10.1016\/j.jcf.2025.06.002_bib0030","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1001\/jama.287.22.2958","article-title":"Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors","volume":"287","author":"West","year":"2002","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jcf.2025.06.002_bib0031","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/(SICI)1099-0496(199911)28:5<321::AID-PPUL3>3.0.CO;2-V","article-title":"Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis","volume":"28","author":"Rosenfeld","year":"1999","journal-title":"Pediatr Pulmonol"},{"issue":"10","key":"10.1016\/j.jcf.2025.06.002_bib0032","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167957","article-title":"PROMISE-micro study group. pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2025.06.002_bib0033","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijid.2023.11.013","article-title":"Registry working group of the German CF registry. use of elexacaftor\/tezacaftor\/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis","volume":"139","author":"Dittrich","year":"2024","journal-title":"Int J Infect Dis"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325015164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325015164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:34:41Z","timestamp":1779953681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325015164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1569199325015164"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.06.002","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monitoring early antibiotic treatment with anti-Pseudomonas aeruginosa serology: a comparison of two specific antibody panels","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}